Viatris Inc

General

Total Cases18

Active Cases4

Patents15

CourtsD. Delaware N.D. West Virginia W.D. Pennsylvania

TypeOperating Company

Elite Ratings

DCT

Ratings

Experience

Grade

Trend

DCT

L5

A

PTAB

L5

A

CAFC

L5

A

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
09/16/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	REDACTED VERSION of [287] Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # [1] Exhibit G, # [2] Exhibit H, # [3] Exhibit I)(Gattuso, Dominick) (Entered: 09/16/2024)
09/16/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	DEFICIENCY NOTICE by the Court issued to Gerbera Therapeutics, Inc. and Nanjing Noratech Pharmaceutical Co. Limited re [296] Redacted Document. Upon review it was determined this filing was not a complete version of what was filed at D.I. [287] . The redaction lacked Exhibit I. Defendants are to file a revised redacted version of D.I. [287] no later than three (3) days from the date of this notice. (nms) (Entered: 09/16/2024) DEFICIENCY NOTICE by the Court issued to Gerbera Therapeutics, Inc. and Nanjing Noratech Pharmaceutical Co. Limited re [296] Redacted Document. Upon review it was determined this filing was not a complete version of what was filed at D.I. [287] . The redaction lacked Exhibit I. Defendants are to file a revised redacted version of D.I. [287] no later than three (3) days from the date of this notice. (nms) (Entered: 09/16/2024)
09/13/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	[SEALED] Joint Letter to The Honorable Richard G. Andrews, from Novartis and MSN, regarding bond pending appeal. (Attachments: # [1] Exhibit A, # [2] Exhibit B, # [3] Exhibit C, # [4] Exhibit D, # [5] Exhibit E, # [6] Exhibit F, # [7] McDuff Declaration, # [8] Chintapally Declaration, # [9] Certificate of Service) (Silver, Daniel) Modified on 9/16/2024 (nms). (Entered: 09/13/2024)
09/13/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	NOTICE to Take Deposition of Jonathan W. Steed, Ph.D. on September 17, 2024 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 09/13/2024)
09/13/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	NOTICE to Take Deposition of Richard L. McCreery, Ph.D. on September 18, 2024 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 09/13/2024)
09/13/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	REDACTED VERSION of [287] Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # [1] Exhibit G, # [2] Exhibit H)(Gattuso, Dominick) (Entered: 09/13/2024)
09/13/24	Momenta Pharmaceuticals Inc v. Mylan Pharmaceuticals Inc 2:22-CV-00750 ( W.D. PA )	CLAIM Construction Chart by MOMENTA PHARMACEUTICALS, INC.. (Attachments: # [1] Appendix Plaintiff's Table of Contents, # [2] Appendix Plaintiff's Ex. B, # [3] Appendix Plaintiff's Ex. C, # [4] Appendix Plaintiff's Ex. D, # [5] Appendix Plaintiff's Ex. E, # [6] Appendix Plaintiff's Ex. F, # [7] Appendix Plaintiff's Ex. G, # [8] Appendix Plaintiff's Ex. H, # [9] Appendix Plaintiff's Ex. I, # [10] Appendix Plaintiff's Ex. J, # [11] Appendix Plaintiff's Ex. K, # [12] Appendix Plaintiff's Ex. L, # [13] Appendix Defendant's Cover Page, # [14] Appendix Defendant's Ex. 1, # [15] Appendix Defendant's Ex. 2, # [16] Appendix Defendant's Ex. 3, # [17] Appendix Defendant's Ex. 4, # [18] Appendix Defendant's Ex. 5, # [19] Appendix Defendant's Ex. 6, # [20] Appendix Defendant's Ex. 7, # [21] Appendix Defendant's Ex. 8, # [22] Appendix Defendant's Ex. 9, # [23] Appendix Defendant's Ex. 10, # [24] Appendix Defendant's Ex. 11, # [25] Appendix Defendant's Ex. 12, # [26] Appendix Defendant's Ex. 13, # [27] Appendix Defendant's Ex. 14, # [28] Appendix Defendant's Ex. 15, # [29] Appendix Defendant's Ex. 16, # [30] Appendix Defendant's Ex. 17, # [31] Appendix Defendant's Ex. 18, # [32] Appendix Defendant's Ex. 19, # [33] Appendix Defendant's Ex. 20, # [34] Appendix Defendant's Ex. 21, # [35] Appendix Defendant's Ex. 22, # [36] Appendix Defendant's Ex. 23a, # [37] Appendix Defendant's Ex. 23b, # [38] Appendix Defendant's Ex. 24, # [39] Appendix Defendant's Ex. 25, # [40] Appendix Defendant's Ex. 26, # [41] Appendix Defendant's Ex. 27, # [42] Appendix Defendant's Ex. 28, # [43] Appendix Defendant's Ex. 29, # [44] Appendix Defendant's Ex. 30, # [45] Appendix Defendant's Ex. 31, # [46] Appendix Defendant's Ex. 32, # [47] Appendix Defendant's Ex. 33, # [48] Appendix Defendant's Ex. 34, # [49] Appendix Defendant's Ex. 35, # [50] Appendix Defendant's Ex. 36, # [51] Appendix Defendant's Ex. 37) (Flynn, Edward) (Entered: 09/13/2024) CLAIM Construction Chart by MOMENTA PHARMACEUTICALS, INC.. (Attachments: # [1] Appendix Plaintiff's Table of Contents, # [2] Appendix Plaintiff's Ex. B, # [3] Appendix Plaintiff's Ex. C, # [4] Appendix Plaintiff's Ex. D, # [5] Appendix Plaintiff's Ex. E, # [6] Appendix Plaintiff's Ex. F, # [7] Appendix Plaintiff's Ex. G, # [8] Appendix Plaintiff's Ex. H, # [9] Appendix Plaintiff's Ex. I, # [10] Appendix Plaintiff's Ex. J, # [11] Appendix Plaintiff's Ex. K, # [12] Appendix Plaintiff's Ex. L, # [13] Appendix Defendant's Cover Page, # [14] Appendix Defendant's Ex. 1, # [15] Appendix Defendant's Ex. 2, # [16] Appendix Defendant's Ex. 3, # [17] Appendix Defendant's Ex. 4, # [18] Appendix Defendant's Ex. 5, # [19] Appendix Defendant's Ex. 6, # [20] Appendix Defendant's Ex. 7, # [21] Appendix Defendant's Ex. 8, # [22] Appendix Defendant's Ex. 9, # [23] Appendix Defendant's Ex. 10, # [24] Appendix Defendant's Ex. 11, # [25] Appendix Defendant's Ex. 12, # [26] Appendix Defendant's Ex. 13, # [27] Appendix Defendant's Ex. 14, # [28] Appendix Defendant's Ex. 15, # [29] Appendix Defendant's Ex. 16, # [30] Appendix Defendant's Ex. 17, # [31] Appendix Defendant's Ex. 18, # [32] Appendix Defendant's Ex. 19, # [33] Appendix Defendant's Ex. 20, # [34] Appendix Defendant's Ex. 21, # [35] Appendix Defendant's Ex. 22, # [36] Appendix Defendant's Ex. 23a, # [37] Appendix Defendant's Ex. 23b, # [38] Appendix Defendant's Ex. 24, # [39] Appendix Defendant's Ex. 25, # [40] Appendix Defendant's Ex. 26, # [41] Appendix Defendant's Ex. 27, # [42] Appendix Defendant's Ex. 28, # [43] Appendix Defendant's Ex. 29, # [44] Appendix Defendant's Ex. 30, # [45] Appendix Defendant's Ex. 31, # [46] Appendix Defendant's Ex. 32, # [47] Appendix Defendant's Ex. 33, # [48] Appendix Defendant's Ex. 34, # [49] Appendix Defendant's Ex. 35, # [50] Appendix Defendant's Ex. 36, # [51] Appendix Defendant's Ex. 37) (Flynn, Edward) (Entered: 09/13/2024)
09/12/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	ORAL ORDER: A joint submission with a proposed order in follow up to The Federal Circuit's September 12, 2024, Order is due by the COB tomorrow (9/13/2024). To the extent the parties cannot agree, they should include arguments in support of their respective positions. Ordered by Judge Richard G. Andrews on 9/12/2024. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:22-cv-01395-RGA(nms) (Entered: 09/12/2024) ORAL ORDER: A joint submission with a proposed order in follow up to The Federal Circuit's September 12, 2024, Order is due by the COB tomorrow (9/13/2024). To the extent the parties cannot agree, they should include arguments in support of their respective positions. Ordered by Judge Richard G. Andrews on 9/12/2024. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:22-cv-01395-RGA(nms) (Entered: 09/12/2024)
09/12/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	ORDER of USCA as to [240] Notice of Appeal (Federal Circuit) filed by Novartis Pharmaceuticals Corporation. Decision of USCA: Upon consideration of the parties' responses to this court's August 22, 2024 order, IT IS ORDERED THAT: Appellants are directed to file a bond in the district court in an amount, and subject to terms and conditions, deemed appropriate by the district court.. (nms) (Entered: 09/12/2024) ORDER of USCA as to [240] Notice of Appeal (Federal Circuit) filed by Novartis Pharmaceuticals Corporation. Decision of USCA: Upon consideration of the parties' responses to this court's August 22, 2024 order, IT IS ORDERED THAT: Appellants are directed to file a bond in the district court in an amount, and subject to terms and conditions, deemed appropriate by the district court.. (nms) (Entered: 09/12/2024)
09/12/24	Bausch Health Ireland Ltd v. Mylan Laboratories Ltd 1:22-CV-00020 ( N.D. WV )	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Reply Expert Report of Dr. Graham Buckton, Ph.D. Regarding Defendants In re Cellect Defense; and Reply Expert Report of Dr. Zhaohui Sunny Zhou, Ph.D., Regarding U.S. Patent No. 11,834,521. (Copland, Gordon) (Entered: 09/12/2024)